In Phase 1 studies, AZD5363 monotherapy showed clinical activity in various heavily pre-treated solid tumors harboring the gain-of-function AKT1 E17K mutation, including ER+ breast, cervical and ovarian cancer, and lung adenocarcinoma [6, 7], and is being tested in multiple basket trials and in combination with chemo- or hormonal therapy in various tumour types. The gene discussed is AKT1; the disease is ovarian carcinoma.